Showing 1 - 20 results of 202 for search '"ТРАНСПОРТЕРЫ"', query time: 0.82s Refine Results
  1. 1
    Academic Journal

    Source: VII Пущинская конференция «Биохимия, физиология и биосферная роль микроорганизмов», шко- ла-конференция для молодых ученых, аспирантов и студентов «Генетические технологии в микробио- логии и микробное разнообразие».

  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
    Academic Journal

    Contributors: The study reported in this publication was carried out as part of publicly funded research project No. 056-00052-23-00 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&D public accounting No. 121022400082-4)., Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 056-00052-23-00 на проведение прикладных научных исследований (номер государственного учета НИР 121022400082-4).

    Source: Safety and Risk of Pharmacotherapy; Том 11, № 2 (2023); 155-164 ; Безопасность и риск фармакотерапии; Том 11, № 2 (2023); 155-164 ; 2619-1164 ; 2312-7821

    File Description: application/pdf

    Relation: https://www.risksafety.ru/jour/article/view/286/782; https://www.risksafety.ru/jour/article/downloadSuppFile/286/365; Huang JX, Kaeslin G, Ranall MV, Blaskovich MA, Becker B, Butler MS, et al. Evaluation of biomarkers for in vitro prediction of drug-induced nephrotoxicity: comparison of HK-2, immortalized human proximal tubule epithelial, and primary cultures of human proximal tubular cells. Pharmacol Res Perspect. 2015;3(3):e00148. https://doi.org/10.1002/prp2.148; Aschauer L, Carta G, Vogelsang N, Schlatter E, Jennings P. Expression of xenobiotic transporters in the human renal proximal tubule cell line RPTEC/TERT1. Toxicol In Vitro. 2015;30(1 Pt A):95–105. https://doi.org/10.1016/j.tiv.2014.12.003; Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney. Nat Rev Nephrol. 2017;13(10):629–46. https://doi.org/10.1038/nrneph.2017.107; Zazuli Z, Otten LS, Drögemöller BI, Medeiros M, Monzon JG, Wright GEB, et al. Outcome definition influences the relationship between genetic polymorphisms of ERCC1, ERCC2, SLC22A2 and cisplatin nephrotoxicity in adult testicular cancer patients. Genes (Basel). 2019;10(5):364. https://doi.org/10.3390/genes10050364; Servais H, Ortiz A, Devuyst O, Denamur S, Tulkens PM, Mingeot-Leclercq MP. Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. Apoptosis. 2008;13(1):11–32. https://doi.org.10.1007/s10495-007-0151-z; Wilmer MJ, Saleem MA, Masereeuw R, Ni L, van der Velden TJ, Russel FG, et al. Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters. Cell Tissue Res. 2010;339(2):449–57. https://doi.org/10.1007/s00441-009-0882-y; Fisel P, Renner O, Nies AT, Schwab M, Schaeffeler E. Solute carrier transporter and drug-related nephrotoxicity: the impact of proximal tubule cell models for preclinical research. Expert Opin Drug Metab Toxicol. 2014;10(3):395–408. https://doi.org/10.1517/17425255.2014.876990; Mac K, Chavada R, Paull S, Howlin K, Wong J. Cefepime induced acute interstitial nephritis — a case report. BMC Nephrol. 2015;16:15. https://doi.org/10.1186/s12882-015-0004-x; https://www.risksafety.ru/jour/article/view/286

  13. 13
    Academic Journal

    Source: Pharmacogenetics and Pharmacogenomics; № 1 (2022); 63-73 ; Фармакогенетика и фармакогеномика; № 1 (2022); 63-73 ; 2686-8849 ; 2588-0527

    File Description: application/pdf

    Relation: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/246/238; Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;0:1–24.; Huang B, Warner M, Gustafsson JA. Estrogen receptors in breast carcinogenesis and endocrine therapy. Mol Cell Endocrinol. 2015;418(Pt 3): 240–4.; Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016 Sep 1;34(25):3069–3103. DOI:10.1200/JCO.2016.67.1487; Sanchez-Spitman AB, Swen JJ, Dezentje VO, Moes DJAR, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. Expert Rev Clin Pharmacol. 2019 Jun;12(6):523–536. DOI:10.1080/17512433.2019.1610390; Brauch H, Mürdter TE, Eichelbaum M, Schwab M. Pharmacogenomics of tamoxifen therapy. Clin Chem. 2009 Oct;55(10):1770–1782. DOI:10.1373/clinchem.2008.121756; Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011 Mar;89(3):464–467. DOI:10.1038/clpt.2010.279; Knox SK, Ingle JN, Suman VJ, et al. Cytochrome P450 2D6 status predicts breast cancer relapse in women receiving adjuvant tamoxifen (Tam). J Clin Oncol. 2006;24(18):4S–4S.; Saladores P, Mürdter T, Eccles D, Chowbay B, Zgheib NK, Winter S, Ganchev B, Eccles B, Gerty S, Tfayli A, Lim JS, Yap YS, Ng RC, Wong NS, Dent R, Habbal MZ, Schaeffeler E, Eichelbaum M, Schroth W, Schwab M, Brauch H. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J. 2015 Feb;15(1):84–94. DOI:10.1038/tpj.2014.34; Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009 Oct 7;302(13):1429–1436. DOI:10.1001/jama.2009.1420; Sanchez-Spitman A, Dezentjé V, Swen J, Moes DJAR, Böhringer S, Batman E, van Druten E, Smorenburg C, van Bochove A, Zeillemaker A, Jongen L, Los M, Neven P, Gelderblom H, Guchelaar HJ. Tamoxifen Pharmacogenetics and Metabolism: Results from the Prospective CYPTAM Study. J Clin Oncol. 2019 Mar 10;37(8):636–646. DOI:10.1200/JCO.18.00307; Binkhorst L, Mathijssen RH, Jager A, van Gelder T. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. Cancer Treat Rev. 2015 Mar;41(3):289–299. DOI:10.1016/j.ctrv.2015.01.002; Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, Purdie CA, Jordan LB, Ferraldeschi R, Latif A, Hadfield KD, Clarke RB, Ashcroft L, Evans DG, Howell A, Nikoloff M, Lawrence J, Newman WG. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat. 2011 Jan;125(1):279–287. DOI:10.1007/s10549-010-1139-x; Joffe H, Deckersbach T, Lin NU, Makris N, Skaar TC, Rauch SL, Dougherty DD, Hall JE. Metabolic activity in the insular cortex and hypothalamus predicts hot flashes: an FDG-PET study. J Clin Endocrinol Metab. 2012 Sep;97(9):3207–3215. DOI:10.1210/jc.2012-1413; Suzanne D Conzen, Lynn Henry N. Managing the side effects of tamoxifen and aromatase inhibitors. Available from: https://www.uptodate.com/contents/managing–the–side–effects–of–tamoxifen–and–aromatase–inhibitors/print?search=tamoxifen.; Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 1994 May 28;343(8909):1318–1321. DOI:10.1016/s0140-6736(94)92466-x; Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005 Dec 20;23(36):9312– 9318. DOI:10.1200/JCO.2005.03.3266; Sensorn I, Sukasem C, Sirachainan E, Chamnanphon M, Pasomsub E, Trachu N, Supavilai P, Pinthong D, Wongwaisayawan S. ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen. Onco Targets Ther. 2016 Apr 12;9:2121–2129. DOI:10.2147/OTT.S100905; Irvin WJ Jr, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, Raab RE, Corso SW, Peppercorn JM, Anderson SM, Friedman KJ, Ogburn ET, Desta Z, Flockhart DA, McLeod HL, Evans JP, Carey LA. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol. 2011 Aug 20;29(24):3232–3239. DOI:10.1200/JCO.2010.31.4427; Dean L. Tamoxifen therapy and CYP2D6 genotype. Source Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–2014 Oct 7. PMID: 28520357. Available from: https://pubmed.ncbi.nlm.nih.gov/28520357/.; Mwinyi J, Vokinger K, Jetter A, Breitenstein U, Hiller C, Kullak- Ublick GA, Trojan A. Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy. Cancer Chemother Pharmacol. 2014 Jun;73(6):1181–1188. DOI:10.1007/s00280-014-2453-5; Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ. Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther. 2011 May;89(5):662–673. DOI:10.1038/clpt.2011.34; Khan BA, Robinson R, Fohner AE, Muzquiz LI, Schilling BD, Beans JA, Olnes MJ, Trawicki L, Frydenlund H, Laukes C, Beatty P, Phillips B, Nickerson D, Howlett K, Dillard DA, Thornton TA, Thummel KE, Woodahl EL. Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People. Clin Transl Sci. 2018 May;11(3):312–321. DOI:10.1111/cts.12542; Cronin-Fenton DP, Damkier P. Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics. Adv Pharmacol. 2018;83:65–91. DOI:10.1016/bs.apha.2018.03.001; Chan CWH, Law BMH, So WKW, Chow KM, Waye MMY. Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen. J Cancer Res Clin Oncol. 2020 Jun;146(6):1395–1404. DOI:10.1007/s00432-020-03206-w

  14. 14
    Academic Journal

    Source: Machines and Plants: Design and Exploiting; № 1 (2023); 53 - 64 ; Машины и установки: проектирование, разработка и эксплуатация; № 1 (2023); 53 - 64 ; 2412-592X

    File Description: application/pdf

    Relation: https://www.maplants-journal.ru/jour/article/view/83/75; https://www.maplants-journal.ru/jour/article/downloadSuppFile/83/38; Малютин Л. Системы подвесок транспортных средств для перевозок тяжеловесных крупногабаритных грузов. // Основные средства. - 2018. - №9.; Белоусов Б.Н., Попов С.Д. Колесные транспортные средства особо большой грузоподъемности. Конструкция. Теория. Расчет. Москва, Изд-во МГТУ им. Н.Э. Баумана, 2006, 728 с.; SPMT Modular Trailer Ultimate Guide [Электронный ресурс]: официальный сайт компании «Anster». URL: https://anstertrailer.com/ (дата обращения: 27.11.2022).; Галерея продукции компании «Cometto» [Электронный ресурс]: официальный сайт компании «Cometto». URL: https://www.cometto.com/ (дата обращения: 26.11.2022).; Диамидов А.С. Развитие перевозок негабаритных грузов большой массы // Итоги науки и техники, 2014.

  15. 15
    Academic Journal

    Source: Modern Rheumatology Journal; Том 17, № 4 (2023); 28-34 ; Современная ревматология; Том 17, № 4 (2023); 28-34 ; 2310-158X ; 1996-7012

    File Description: application/pdf

    Relation: https://mrj.ima-press.net/mrj/article/view/1456/1381; Насонов ЕЛ. Проблемы иммунопатологии ревматоидного артрита: эволюция болезни. Научно-практическая ревматология. 2017;55(3):277-294.; Фоломеева ОМ, Насонов ЕЛ, Андрианова ИА и др. Ревматоидный артрит в ревматологической практике России: тяжесть заболевания в российской популяции больных. Одномоментное (поперечное) эпидемиологическое исследование (RAISER). Научно-практическая ревматология. 2010;48(1):50-60.; Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Jun;76(6):960-977. doi:10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6.; Сычев ДА, Муслимова ОВ, Гаврисюк ЕВ и др. Фармакогенетические технологии персонализированной медицины: оптимизация применения лекарственных средств. Terra medica. 2011;(1):4-9.; Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine. 2019 May;86(3):301-307. doi:10.1016/j.jbspin.2018.07.004. Epub 2018 Aug 3; Dervieux T, Wessels JAM, van der Straaten T, et al. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet (enomics. 2009 Dec;19(12):935-44. doi:10.1097/FPC.0b013e32833315d1; Brown LD, Cai TT, Das Gupta A. Interval Estimation for a proportion. Statistical Science. 2001;16(2):101-133.; Sokal RR, Rohlf FJ. Biometry: the principles and practice of statistics in biological research. New York: Freeman & Co; 1995. 850 p.; Sergeant ESG. Epitools epidemiological calculators. http://epitools.ausvet.com.au/content.php?page=CIProportion; Hammer О, Harper DAT, Ryan PD. PAST: Paleontological statistics software package for education and data analysis. Palaeontologia Electronica. 2001;(1):1-9.; Григорьев СГ, Лобзин ЮВ, Скрипченко НВ. Роль и место логистической регрессии и ROC-анализа в решении медицинских диагностических задач. Журнал инфектологии. 2016;8(4):36-45.; Пономаренко ИВ. Использование метода Multifactor Dimensionality Reduction (MDR) и его модификаций для анализа ген-генных и генно-средовых взаимодействий при генетико-эпидемиологических исследованиях (обзор). Научные результаты биомедицинских исследований. 2019; 5(1):4-21.; Samara S, Irshaid Y, Mustafa K. Association of MDR1 3435C>T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients. Int J Clin Pharmacol Ther. 2014 Sep; 52(9):746-55. doi:10.5414/CP202098.; Muralidharan N, Mariaselvam CM, Mit-hun CB, Negi VS. Reduced folate carrier-1 80G>A gene polymorphism is not associated with methotrexate treatment response in So-uth Indian Tamils with rheumatoid arthritis. Clin Rheumatol. 2016 Apr;35(4):879-85. doi:10.1007/s10067-015-2917-y. Epub 2015 Mar 15.; Muralidharan N, Antony PT, Jain VK, et al. Multidrug resistance 1 (MDR1) 3435C>T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis. Eur J Clin Pharmacol. 2015 Aug;71(8): 959-65. doi:10.1007/s00228-015-1885-0. Epub 2015 Jun 14.; Boughrara W, Benzaoui A, Aberkane M, et al. No correlation between MTHFR c.677 C>T, MTHFR c.1298 A>C, and ABCB1 c.3435 C>T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population. Inflamm Res. 2017 Jun;66(6):505-513. doi:10.1007/s00011-017-1034-6. Epub 2017 Mar 15.; Swierkot J, Slezak R, Karpinski P, et al. Associations between single-nucleotide poly-morphisms of RFC-1, GGH, MTHFR, TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis. Pol Arch Med Wewn. 2015;125(3):152-61. doi:10.20452/pamw.2707. Epub 2015 Jan 19.; Drozdzik M, Rudas T, Pawlik A, et al. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J. 2007 Dec;7(6):404-7. doi:10.1038/sj.tpj.6500438. Epub 2007 Feb 27.; Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, et al. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2004 Sep;42(9): 496-503. doi:10.5414/cpp42496.; Takatori R, Takahashi KA, Tokunaga D, et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol. 2006 Sep-Oct;24(5):546-54.; El Fedawy SF, Shehab A, Rania A, et al. The Influence of the MDR1 3435C>T Poly-morphism on Methotrexate Responsiveness in Rheumatoid Arthritis Patients. Egypt J Hosp Med. 2020;80(2):857-864. doi:10.12816/EJHM.2020.98917.; Dervieux T, Kremer J, Lein DO, et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamyl-hydrolase to methotrexate polyglutamate le-vels in patients with rheumatoid arthritis. Pharmacogenetics. 2004 Nov;14(11):733-9. doi:10.1097/00008571-200411000-00004.; Rangannathan P, McLeod H. Methotre-xate pharmacogenetics. The first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum. 2006 May;54(5):1366-77. doi:10.1002/art.21762.; Lima A, Bernardes M, Azevedo R, et al. Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome. Pharmacogenomics. 2016 Oct;17(15):1649-1674. doi:10.2217/pgs-2016-0067. Epub 2016 Sep 27.

  16. 16
    Academic Journal

    Contributors: The study reported in this publication was carried out as part of publicly funded research project No. 056- 00052-23-00 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&D registration No. 121022400082-4)., Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 056- 00052-23-00 на проведение прикладных научных исследований (номер государственного учета НИР 121022400082-4)

    Source: Regulatory Research and Medicine Evaluation; Том 13, № 4 (2023); 560-566 ; Регуляторные исследования и экспертиза лекарственных средств; Том 13, № 4 (2023); 560-566 ; 3034-3453 ; 3034-3062

    File Description: application/pdf

    Relation: https://www.vedomostincesmp.ru/jour/article/view/557/1219; https://www.vedomostincesmp.ru/jour/article/view/557/1227; https://www.vedomostincesmp.ru/jour/article/view/557/1236; https://www.vedomostincesmp.ru/jour/article/view/557/1246; Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol. 2008;48(6):662–70. https://doi.org/10.1177/0091270007312153; DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87(3):272–7. https://doi.org/10.1038/clpt.2009.295; Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9(3):203–14. https://doi.org/10.1038/nrd3078; Zamek-Gliszczynski MJ, Sangha V, Shen H, Feng B, Wittmer MB, Varma MVS, et al. Transporters in drug development: International transporter consortium update on emerging transporters of clinical importance. Clin Pharmacol Ther. 2022;112(3):485–500. https://doi.org/10.1002/cpt.2644; Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–36. https://doi.org/10.1038/nrd3028; Iusuf D, Sparidans RW, van Esch A, Hobbs M, Kenworthy KE, van de Steeg E, et al. Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice. Mol Pharm. 2012;9(9):2497–504. https://doi.org/10.1021/mp300108c; Vlaming ML, Pala Z, van Esch A, Wagenaar E, de Waart DR, van de Wetering K, et al. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin Cancer Res. 2009;15(9):3084–93. https://doi.org/10.1158/1078-0432.ccr-08-2940; Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006;17(8):2127–35. https://doi.org/10.1681/asn.2006030205; Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H, et al. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug–drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther. 2012;340(2):393–403. https://doi.org/10.1124/jpet.111.184986; Tsuda M, Terada T, Ueba M, Sato T, Masuda S, Katsura T, et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther. 2009;329(1):185–91. https://doi.org/10.1124/jpet.108.147918; Frymoyer A, Shugarts S, Browne M, Wu AHB, Frassetto L, Benet LZ. Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers. Clin Pharmacol Ther. 2010;88(4):540–7. https://doi.org/10.1038/clpt.2010.142; Bihorel S, Camenisch G, Lemaire M, Scherrmann JM. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res. 2007;24(9):1720–8. https://doi.org/10.1007/s11095-007-9278-4; Oostendorp RL, Buckle T, Beijnen JH, van Tellingen O, Schellens JHM. The effect of Pgp (Mdr1a/1b), BCRP (Bcrp1) and Pgp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs. 2009;27(1):31–40. https://doi.org/10.1007/s10637-008-9138-z; Chen C, Stock JL, Liu X, Shi J, Van Deusen JW, Di- Mattia DA, et al. Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds. Drug Metab Dispos. 2008;36(9):1840–5. https://doi.org/10.1124/dmd.108.020594; Chu XY, Strauss JR, Mariano MA, Li J, Newton DJ, Cai X, et al. Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). J Pharmacol Exp Ther. 2006;317(2):579–89. https://doi.org/10.1124/jpet.105.098665; https://www.vedomostincesmp.ru/jour/article/view/557

  17. 17
  18. 18
  19. 19
  20. 20